KORU Medical Systems, Inc. (KRMD)
Healthcare · NCM
Price as at 1 Oct 2026, 20:15 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
KORU Medical Systems, Inc. trades at $3.02, which is 46% above the $1.63 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 45 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
KRMD earnings and analyst estimates
Recommendation mix, 5 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About KORU Medical Systems, Inc.
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
KRMD passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$692.6K · 0.0% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$222.1K · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$119.8K · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$90.3K · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$68.7K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
KRMD peers
The largest companies in the same industry (Medical Instruments & Supplies), then in the same sector.
- MDLN Medline Inc.
- RSMDF ResMed Inc.
- SRT3.DE Sartorius Aktiengesellschaft
- SOLV Solventum Corporation
- BAX Baxter International Inc.
- RGEN Repligen Corporation
- AVTR Avantor, Inc.
- TFX Teleflex Incorporated
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is KORU Medical Systems, Inc. (KRMD) undervalued?
Against our fair value estimate of $1.63, KRMD at $3.02 is 46% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own KRMD?
6 of the institutions we track reported a position in KRMD in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its KRMD data?
Fundamentals for KRMD come from company filings and exchange data, as listed on NCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 20:15 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for KRMD, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.